Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects With Advanced Solid Tumors

Trial Profile

Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects With Advanced Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs BMS 986115 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Cholangiocarcinoma; Colon cancer; Fibroma; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Rectal cancer; Renal cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 10 Apr 2018 Results assessing safety, pharmacokinetics, pharmacodynamics and preliminary anti tumor activity published in the Investigational New Drugs
    • 30 Aug 2016 Status changed from completed to discontinued due to non-safety reason, business objectives have changed.
    • 29 Aug 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top